Table 2.

Summary of PD-L1 assay information and scoring system in constituent trials.

				Criteria (Cutoffs)
Study Name	PD-L1 Antibody Clone	IHC Assay Provider	Interpretative Scoring	Negative	Weak-positive	Strong-positive	Percentage of Strong PD-L1 Expression Subgroup among Evaluable Population
CheckMate 017	28–8	Dako North America	TC membrane	<1%	≥1% and <5%	≥5%	81/225, 36.0%
CheckMate 057	28–8	Dako North America	TC membrane	<1%	≥1% and <5%	≥5%	181/455, 39.8%
CheckMate 026	28–8	Dako North America	TC membrane		≥1% and <5%	≥5%	423/1325, 31.9%
KEYNOTE-010	22C3	Dako North America	TC membrane	<1%	≥1% and <50%	≥50%	633/2222, 28.5%
KEYNOTE-024	22C3	Dako North America	TC membrane			≥50%	500/1653, 30.2%
POPLAR	SP142	Ventana Medical Systems, AZ, USA	TC membrane Infiltrating ICs	<1%	≥1% and <5%	≥5%	105/287, 37%
OAK	SP142	Ventana Medical Systems, AZ, USA	TC membrane Infiltrating ICs	<1%	≥1% and <5%	≥5%	265/850, 31%

Abbreviation: TC, tumor cell; IC, immune cells